189 related articles for article (PubMed ID: 31870123)
41. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
Zou Y; Ling YH; Sironi J; Schwartz EL; Perez-Soler R; Piperdi B
J Thorac Oncol; 2013 Jun; 8(6):693-702. PubMed ID: 23575415
[TBL] [Abstract][Full Text] [Related]
42. Chloroquine potentiates the anti-cancer effect of lidamycin on non-small cell lung cancer cells in vitro.
Liu F; Shang Y; Chen SZ
Acta Pharmacol Sin; 2014 May; 35(5):645-52. PubMed ID: 24727941
[TBL] [Abstract][Full Text] [Related]
43. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
Soo RA; Wang LZ; Tham LS; Yong WP; Boyer M; Lim HL; Lee HS; Millward M; Liang S; Beale P; Lee SC; Goh BC
Ann Oncol; 2006 Jul; 17(7):1128-33. PubMed ID: 16670205
[TBL] [Abstract][Full Text] [Related]
44. Targeting Autophagy With the Synergistic Combination of Chloroquine and Rapamycin as a Novel Effective Treatment for Well-differentiated Liposarcoma.
Masaki N; Aoki Y; Obara K; Kubota Y; Bouvet M; Miyazaki J; Hoffman RM
Cancer Genomics Proteomics; 2023; 20(4):317-322. PubMed ID: 37400145
[TBL] [Abstract][Full Text] [Related]
45. Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
Firouzabadi D; Dehghanian A; Rezvani A; Mahmoudi L; Talei A
BMC Cancer; 2021 Jan; 21(1):47. PubMed ID: 33430808
[TBL] [Abstract][Full Text] [Related]
46. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Wang LR; Huang MZ; Zhang GB; Xu N; Wu XH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):601-7. PubMed ID: 17549479
[TBL] [Abstract][Full Text] [Related]
47. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
Liang DH; Choi DS; Ensor JE; Kaipparettu BA; Bass BL; Chang JC
Cancer Lett; 2016 Jul; 376(2):249-58. PubMed ID: 27060208
[TBL] [Abstract][Full Text] [Related]
48. Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment.
Song YJ; Zhang SS; Guo XL; Sun K; Han ZP; Li R; Zhao QD; Deng WJ; Xie XQ; Zhang JW; Wu MC; Wei LX
Cancer Lett; 2013 Oct; 339(1):70-81. PubMed ID: 23879969
[TBL] [Abstract][Full Text] [Related]
49. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
Hainsworth JD; Burris HA; Erland JB; Morrissey LH; Meluch AA; Kalman LA; Hon JK; Scullin DC; Smith SW; Greco FA
Cancer; 1999 Mar; 85(6):1269-76. PubMed ID: 10189131
[TBL] [Abstract][Full Text] [Related]
50. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.
Barnard RA; Wittenburg LA; Amaravadi RK; Gustafson DL; Thorburn A; Thamm DH
Autophagy; 2014 Aug; 10(8):1415-25. PubMed ID: 24991836
[TBL] [Abstract][Full Text] [Related]
51. A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.
Massard C; Cassier PA; Azaro A; Anderson B; Yuen E; Yu D; Oakley G; Benhadji KA; Pant S
Cancer Chemother Pharmacol; 2022 Oct; 90(4):335-344. PubMed ID: 36030462
[TBL] [Abstract][Full Text] [Related]
52. Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
Soetekouw PM; Timmer-Bonte JN; van der Drift MA; van Leeuwen F; Wagenaar M; van Die L; Bussink J; Tjan-Heijnen VC
Int J Clin Oncol; 2013 Dec; 18(6):988-96. PubMed ID: 23011101
[TBL] [Abstract][Full Text] [Related]
53. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
[TBL] [Abstract][Full Text] [Related]
54. [Chloroquine Enhances BIIB021-induced Apoptosis in Chronic Myeloid Leukemia Cells Bearing T315I Mutation].
He W; Zhao CF; Chen L; Hu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1005-1010. PubMed ID: 35981354
[TBL] [Abstract][Full Text] [Related]
55. Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.
Goldwasser F; Faivre S; Alexandre J; Coronado C; Fernández-García EM; Kahatt CM; Paramio PG; Dios JL; Miguel-Lillo B; Raymond E
Invest New Drugs; 2014 Jun; 32(3):500-9. PubMed ID: 24395456
[TBL] [Abstract][Full Text] [Related]
56. Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer.
Langer CJ; Gandara DR; Calvert P; Edelman MJ; Ozols RF
Semin Oncol; 1999 Feb; 26(1 Suppl 4):12-8. PubMed ID: 10201516
[TBL] [Abstract][Full Text] [Related]
57. PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer.
Rebecca VW; Nicastri MC; Fennelly C; Chude CI; Barber-Rotenberg JS; Ronghe A; McAfee Q; McLaughlin NP; Zhang G; Goldman AR; Ojha R; Piao S; Noguera-Ortega E; Martorella A; Alicea GM; Lee JJ; Schuchter LM; Xu X; Herlyn M; Marmorstein R; Gimotty PA; Speicher DW; Winkler JD; Amaravadi RK
Cancer Discov; 2019 Feb; 9(2):220-229. PubMed ID: 30442709
[TBL] [Abstract][Full Text] [Related]
58. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
[TBL] [Abstract][Full Text] [Related]
59. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
60. Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer.
Samaras P; Tusup M; Nguyen-Kim TDL; Seifert B; Bachmann H; von Moos R; Knuth A; Pascolo S
Cancer Chemother Pharmacol; 2017 Nov; 80(5):1005-1012. PubMed ID: 28980060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
